The seven French health competitiveness clusters create a network

To increase the visibility of their 1,300 members, including 1,000 SMEs, and promote their economic value, the health clusters will speak with one voice

Paris, April 11, 2018 - The seven French health competitiveness clusters - Alsace BioValley, Atlanpole Biotherapies, Cancer-Bio-Santé, Eurobiomed, Lyonbiopole, Medicen Paris Region and Nutrition-Health-Longevity - announce today that they are stengthening their collaboration to highlight the results of the activities they have undertaken since 2005 for the benefit of the health sector in France and abroad.

Together, these clusters count 1,300 members, including 1,000 SMEs. Large companies, academic institutions, local authorities, hospitals and healthcare facilities reinforce this unique and dynamic ecosystem. Close to 1,000 members, including 748 SMEs, have already participated in projects certified by the clusters, which represent nearly €5 billion ($6.2bn). These resulted in the marketing of 400 products and services, as well as the creation of 54 companies.

Building on this success, the seven clusters decided to intensify their common activities in order to recognize the innovation capacity of their members as well as the combined economic value of the health industries they represent.

"We are delighted to develop the networking activities of the seven health competitiveness clusters. This will give a new boost to existing inter-cluster actions that we started in 2014. In view of the next development phase for the competitiveness clusters, we are organizing ourselves to multiply and structure these actions," the seven presidents of the clusters said in a joint statement. "Together, we are stronger and offer more opportunities to our members. The consolidated figures show the impact the clusters have on the French economy. We will continue our mission to boost employment, improve the attractiveness of regions and re-industrialize France."

The competitiveness cluster policy was initiated in 2004 to mobilize key factors of competitiveness and to drive growth and employment in promising markets. Competitiveness clusters act in public/private cooperation, together with research entities, industry organizations, SMEs, large groups and training bodies to develop synergies and enhance cooperation. They are present throughout the country, where they contribute by transforming scientific and technological knowledge into therapeutic and economic value.

About Alsace BioValley
As a French world-class cluster dedicated to therapeutic innovations, Alsace BioValley is the one-stop contact to optimize any R&D development or business project in Europe, both in drug development and medical technologies.

Located in the Alsace region, part of the famous French-German-Swiss BioValley and with a unique concentration of international life sciences and healthcare players, Alsace BioValley helps any life science and healthcare companies interested in new projects and partnerships in Europe: to search outstanding scientific or commercial partners to develop innovative R&D projects, to find the best technology, patent or scientific expertise or to set up a company and locate it in the Alsace region.
Alsace BioValley has also agreements with CQDM (Quebec), MLSC (Massachusetts, USA), JBA (Japan Bioidustry Association) and Biopro (Germany).
www.alsace-biovalley.com/en/

About Atlanpole Biotherapies
Atlanpole Biotherapies is an international competitiveness cluster focused on biotherapy, approved by the Ministry of Industry (July 2005). Atlanpole Biotherapies unites the skills of laboratories, platforms and companies for a complete, relevant and competitive public-private offering on the bio-medicine value chain from target discovery to clinical evaluation. The cluster participates in the construction of the medicine of tomorrow in four key areas:

- Immunotherapy
- Radiopharmaceuticals
- Regenerative medicine
- Innovative technologies for biotherapies, particularly for personalized medicine with the exploitation of smart data

Based in the Pays de la Loire - Brittany - Center Val de Loire regions, the cluster has 170 members throughout the country, including 120 SMEs in the biotherapies sector. The cluster sits on the board of CEBR (Council of European BioRegions).
www.atlanpolebiotherapies.com

About the Cancer-Bio-Santé Cluster
The Cancer-Bio-Santé Cluster is bi-regional: Midi-Pyrénées and Limousin. It aims to strengthen the competitiveness of companies through innovation and by creating value through encouraging the emergence of innovative products for the healthcare industry. Its activities are part of a collaborative environment at the interface of academic and private research entities, industry and training organizations. Since it was established in 2005, when it was dedicated to oncology, its sphere of activity has expanded in the context of phase 3 of the competitiveness clusters' policy with the dual themes of oncology and aging. Its main lines of action comprise four Strategic Areas of Activity (DAS), DAS1: ‘Prevention, Nutrition, Environment’, DAS2: ‘Molecules of therapeutic and diagnostic value’, DAS3: ‘Technological innovations - Imaging - Medical devices’, DAS4: ‘Homecare - e-health’ Since early 2016, the cluster has engaged in the emergence of health projects based on aerospace technologies. At the end of 2017, the Cancer-Bio-Santé Cluster federated 104 members; it has approved 205 collaborative R&D projects of which 96 were selected for a total financing of €109.8 million ($135.3M).
www.cancerbiosante.fr

About Eurobiomed
Founded in 2009 by stakeholders in the health sector in the Occitanie Est and Provence-Alpes Côte d'Azur regions, the EUROBIOMED competitiveness cluster brings together all players in the region: teaching, basic research, translational and clinical research, technological innovation centers, start-ups and industrial success stories. EUROBIOMED is above all a collective that aims to develop the interactions between actors in the sector, to support innovation and growth of the sector and of the public and private actors as well as to be an partner for public authorities to help them find answers to the challenges of this industry. Together, the 270 members of the EUROBIOMED collective (including 225 companies) constitute a formidable engine of regional development (172 R&D projects representing €718 million ($885M) in investments and 700 direct jobs). EUROBIOMED offers resources and dedicated solutions to companies and research organizations in the health sector to help them innovate, finance, develop and achieve their strategic and commercial objectives in order to ultimately improve the quality of healthcare, as well as to improve the lives of patients. Based in Marseille, Nice/Sophia-Antipolis and Montpellier, EUROBIOMED has a staff of 11 people. It is chaired by Xavier Tabary with Émilie Royère as its general manager.
www.eurobiomed.com

About Lyonihiopôle
As a biocluster, Lyonihiopôle is the one-stop shop for healthcare innovation in Rhône-Alpes, France. It aims to support the emergence and development of innovative technologies, products and services in four main strategic areas: human medicine, veterinary medicine, in vitro diagnostics, medical devices and medical technologies. Focused on infectious diseases since its creation in 2005, Lyonihiopôle now supports ambitious projects and companies in other fields such as cancer, nutrition, metabolic diseases and neurosciences. At the end of 2017, Lyonihiopôle represented a community of 208 members; with six world-class leaders as Lyonbiopôle’s founders (Sanofi Pasteur, bioMérieux, Merial, BD, the CEA and the Merieux Foundation), 12 subsidiaries of international groups, 175 SMEs and midcaps and 15 Competence Centers (University Teaching Hospitals, Universities, Foundations ...). It has the Gold Label of the European Cluster Excellence Initiative.
www.lyonihiopôle.com
About Medicen Paris Region
Medicen Paris Region is a competitiveness cluster for innovative health technologies, with national and international scope. With more than 350 companies, research centers, universities, hospitals and local authorities as members, it aims to position the Paris region as Europe’s leading healthcare cluster. It focuses on five strategic areas: biological diagnostics, diagnostic and interventional imaging, regenerative medicine and biomaterials, digital health and translational medicine. In close collaboration with local, regional and national healthcare innovation players, Medicen Paris Region aims to:

- Foster the emergence, development and funding of certified collaborative projects in the healthcare sector, in order to create economic value and jobs
- Increase the international development of innovative startups and SMEs
- Strengthen the attractiveness of the Paris region, which represents more than 50% of life sciences activity in France

Since the creation of the cluster in 2005, 62 innovative products have been launched in the imaging, medical devices and biological tools sectors. The cluster has certified 292 projects. They received funding from the French government (French Inter-Ministry Fund FUI, Structuring Projects fund), the public investment bank Bpifrance, the National Research Agency, the European Regional Development Fund, the Investments for the Future program and/or local authorities, and the Paris region. Total investment is close to €1.9 billion ($2.3bn) and $533 million ($635M) of public aid.

www.medicen.org

About NHL Cluster
The Nutrition Health Longevity Competitiveness Cluster (NSL) now has more than 120 members from the agrifood, pharmaceutical and biotechnology sectors, as well as research centers invested in the field of health nutrition. At the crossroads of new medical, scientific and industrial strategies, NSL has become a key player in its field of expertise for networking private research and public research. Its mission is to contribute to the development of its members in two fast-growing markets: foods and functional ingredients and drug treatments for metabolic diseases and pathologies related to aging. Since the creation of the cluster in 2005, 250 projects have been certified, more than 100 of them have obtained an average funding of €1 million ($1.2M). The NSL Pole has supported more than 20 projects in the Investment of the Future Program for a total funding of €150 million ($185M), including support for academic research excellence on diabetes and neurodegenerative diseases. It helped bring more than 30 products and services to market.

www.nhl-cluster.com

Press and analysts contacts
Andrew Lloyd & Associates
Agnes Stephens / Kübra Somuncu
agnes@ala.com - kubra@ala.com
Tel : +44 1273 675 100
@ALA_Group